| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1271.3B | ¥1213.2B | +4.8% |
| Operating Income | ¥323.3B | ¥327.5B | -1.3% |
| Profit Before Tax | ¥332.3B | ¥334.4B | -0.6% |
| Net Income | ¥258.5B | ¥285.6B | -9.5% |
| ROE | 9.1% | 11.5% | - |
FY2026 Q3 consolidated results for Nippon Shinyaku show revenue of 127.1B yen (YoY +4.8%) and operating income of 32.3B yen (YoY -1.3%). Ordinary income reached 33.2B yen (YoY -0.8%) while net income attributable to owners was 25.8B yen (YoY -9.5%). The company maintained revenue growth momentum while experiencing modest profit decline, primarily driven by working capital expansion that pressured cash conversion efficiency despite maintaining high operating margins above 25%.
Revenue increased 5.8B yen from 121.3B yen to 127.1B yen, representing growth of 4.8% year-over-year. The top-line expansion reflects continued sales momentum across the pharmaceutical portfolio. Cost of sales rose proportionally, resulting in gross profit of 85.1B yen and a gross margin of 67.0%, indicating strong pricing power and favorable product mix. Operating profit declined 4.2B yen from 32.8B yen to 32.3B yen, down 1.3% year-over-year, as selling, general and administrative expenses totaled 31.7B yen while R&D expenses reached 23.0B yen. The R&D intensity remained elevated at 18.1% of revenue, reflecting ongoing investment in pipeline development. Operating margin compressed slightly to 25.4% from 27.0% in the prior year period. The gap between operating income of 32.3B yen and ordinary income of 33.2B yen indicates net non-operating income contribution of approximately 0.9B yen. Net income of 25.8B yen reflects a 9.5% decline from 28.6B yen in the prior year, with the decrease driven by higher effective tax burden and potential extraordinary factors. Comprehensive income reached 45.2B yen, substantially exceeding net income due to 19.3B yen in other comprehensive income, primarily from fair value gains on financial assets. This represents a revenue up, profit down pattern, where top-line growth was offset by cost pressures and working capital inefficiencies that limited operating cash generation.
[Profitability] ROE of 9.1% demonstrates adequate return on equity, though operating margin of 25.4% declined 1.6pt from the prior period of 27.0%. Net profit margin stood at 20.3%, indicating strong bottom-line profitability despite compression from the prior year. R&D intensity reached 18.1% of revenue, reflecting sustained commitment to pharmaceutical innovation. [Cash Quality] Cash and cash equivalents totaled 60.8B yen, providing substantial liquidity. Operating cash flow of 12.0B yen represented only 0.46 times net income, indicating weak cash conversion and raising concerns about earnings quality. Free cash flow of 13.5B yen covered dividend payments of 8.1B yen with coverage ratio of 1.55 times. [Investment Efficiency] Total asset turnover of 0.387 times reflects capital-intensive business model. Accounts receivable increased sharply to 53.7B yen from 42.3B yen, extending days sales outstanding to 154 days. Inventory rose to 48.6B yen from 42.5B yen, resulting in days inventory outstanding of 422 days. Cash conversion cycle reached 412 days, indicating significant working capital inefficiency. [Financial Health] Equity ratio of 86.5% demonstrates exceptionally strong financial stability with total equity of 284.2B yen against total assets of 328.1B yen. Debt-to-equity ratio of 0.15 times reflects conservative capital structure with minimal leverage risk.
Operating cash flow of 12.0B yen represents 0.46 times net income, indicating substantial gap between accrual earnings and cash realization. Operating cash flow before working capital changes totaled 20.7B yen, but was significantly reduced by accounts receivable increase of 11.2B yen and inventory buildup of 6.0B yen, reflecting deteriorating working capital efficiency. Investing cash flow totaled positive 15.2B yen, primarily driven by sale or maturity of investment securities that generated proceeds exceeding capital expenditures of 2.3B yen. Financing cash flow of negative 9.2B yen reflected dividend payments of 8.1B yen to shareholders. Free cash flow of 13.5B yen demonstrates ability to cover shareholder distributions while maintaining liquidity buffer. Cash and deposits increased 18.7B yen year-over-year to 60.8B yen despite weak operating cash generation, supported by investment liquidation activities. The sharp expansion in accounts receivable at 26.9% growth and inventory at 14.4% growth substantially outpaced revenue growth of 4.8%, signaling collection delays or extended credit terms alongside potential demand-supply mismatches in inventory management.
Ordinary income of 33.2B yen versus operating income of 32.3B yen shows net non-operating income contribution of approximately 0.9B yen. Non-operating income components include equity method investment gains and financial income as primary elements. Non-operating income represents 0.7% of revenue, consisting primarily of interest and dividend income alongside foreign exchange impacts. Operating cash flow of 12.0B yen falling significantly short of net income of 25.8B yen raises material earnings quality concerns, with cash conversion ratio of 0.46 indicating that less than half of reported profits converted to operating cash. Accrual ratio of 4.2% remains within acceptable range but elevated working capital absorption reflects either aggressive revenue recognition practices or operational inefficiencies in collections and inventory management. The comprehensive income of 45.2B yen substantially exceeding net income by 19.3B yen stems from unrealized gains on financial assets measured at fair value, introducing volatility to equity but not affecting operational cash generation.
Full-year guidance calls for revenue of 170.0B yen, operating income of 33.0B yen, and net income attributable to owners of 26.3B yen. Q3 cumulative revenue of 127.1B yen represents 74.8% progress against the annual target, tracking ahead of the standard 75% benchmark. Operating income of 32.3B yen cumulative through Q3 achieves 97.9% of the full-year target of 33.0B yen, indicating substantial front-loading and suggesting potential downside risk to Q4 operating performance. Net income of 25.8B yen cumulative represents 98.1% of the full-year forecast of 26.3B yen, similarly indicating minimal contribution expected from Q4. The full-year guidance implies YoY declines of 6.9% in operating income and 19.2% in net income despite revenue growth expectations, reflecting anticipated margin compression and profit headwinds in the fiscal year. Progress rates substantially exceeding 75% at Q3 for profit metrics suggest either conservative full-year guidance or expectation of material Q4 deterioration.
Annual dividend per share stands at 62 yen for the fiscal year, consisting of interim dividend of 62 yen. Dividend payments totaled 8.1B yen during the nine-month period. Payout ratio calculated against net income of 25.8B yen cumulative reaches 31.3%, representing sustainable distribution level well below earnings. The company maintains stable dividend policy with commitment to annual distribution of 62 yen per share. Share buyback activities were not disclosed in the current period. Total return ratio aligns with payout ratio at approximately 31.3% given absence of repurchase programs, indicating conservative capital allocation weighted toward balance sheet strength over shareholder returns.
Working capital deterioration risk poses immediate operational concern, with accounts receivable increasing 26.9% and inventory up 14.4% while revenue grew only 4.8%, resulting in days sales outstanding of 154 days and days inventory outstanding of 422 days. This working capital expansion absorbed 17.2B yen of operating cash flow, raising risks of collection difficulties or inventory obsolescence. Pharmaceutical development pipeline risk remains material given R&D expenditures of 23.0B yen representing 18.1% of revenue, with uncertain timing and probability of clinical trial success, regulatory approvals, and commercial viability of pipeline candidates. Profit margin compression risk evident in operating margin declining from 27.0% to 25.4% and net income falling 9.5% despite revenue growth of 4.8%, driven by rising SG&A costs that increased faster than sales, threatening profitability sustainability if cost discipline does not improve.
[Industry Position] (Reference - Proprietary Analysis) Profitability: Operating margin of 25.4% substantially exceeds pharmaceutical industry median of negative 218.2% (IQR: negative 628.8% to negative 14.9%), positioning Nippon Shinyaku in the top tier of operational efficiency within the sector. Net profit margin of 20.3% similarly outperforms industry median of negative 216.8%, reflecting the company's established commercial portfolio versus peers with predominantly development-stage assets. ROE of 9.1% contrasts favorably against industry median of negative 35.8%, though remains modest in absolute terms. Financial Health: Equity ratio of 86.5% exceeds pharmaceutical industry median of 67.8% (IQR: 62.1% to 79.1%), demonstrating superior financial stability and minimal leverage compared to sector peers. Current ratio positioning could not be precisely determined but cash holdings appear adequate relative to industry median of 6.62 times. Efficiency: Asset turnover of 0.387 times exceeds pharmaceutical industry median of 0.17 times (IQR: 0.05 to 0.24), indicating superior capital efficiency despite working capital challenges. Days sales outstanding of 154 days aligns closely with industry median of 151.6 days, suggesting collection patterns consistent with sector norms. Days inventory outstanding of 422 days substantially exceeds industry median of 281.6 days, highlighting inventory management as specific operational weakness. Cash conversion ratio of 0.46 times approximates industry median of 0.41 times, indicating sector-wide challenges in converting accrual earnings to cash. (Industry: Pharmaceuticals, 13 companies analyzed, Comparison: 2025-Q3 fiscal periods, Source: Proprietary analysis)
Nippon Shinyaku demonstrates rare profitability leadership within the pharmaceutical sector, achieving positive operating margin of 25.4% and net profit margin of 20.3% in stark contrast to industry medians showing widespread losses, reflecting successful commercialization of approved products versus development-stage peers. The company's working capital efficiency deterioration represents key operational challenge, with days inventory outstanding of 422 days exceeding industry median by 50% and absorbing 17.2B yen of operating cash during the nine-month period through accounts receivable and inventory expansion substantially outpacing revenue growth. Financial fortress balance sheet with equity ratio of 86.5% and cash holdings of 60.8B yen provides substantial buffer for continued R&D investment at 18.1% of revenue and sustainable dividends with payout ratio of 31.3%, though near-complete achievement of full-year profit guidance by Q3 suggests limited upside potential and possible margin pressure in Q4.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.